HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti-EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Takegawa, Naoki, Yonesaka, Kimio, Sakai, Kazuko, Ueda, Hiroto, Watanabe, Satomi, Nonagase, Yoshikane, Okuno, Tatsuya, Takeda, Masayuki, Maenishi, Osamu, Tsurutani, Junji, Satoh, Taroh, Okamoto, Isamu, Nishio, Kazuto, Tamura, Takao, Nakagawa, Kazuhiko
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2015
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4823119/
https://ncbi.nlm.nih.gov/pubmed/26657506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6498
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares